Clinical trials: Rituximab, completed
Lymphoma, Leukemia
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
The goal of this clinical research study is to see if low intensity chemotherapy given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells from a donor can increase the length of…
- Trial name
- NCT00048737
- Testing
- Zevalin Radioimmunotherapy, Rituximab, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Graft vs Host Disease
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
The addition of rituximab to prednisone for the initial treatment of chronic GVHD will increase the overall response rate, enable a more rapid and effective steroid taper.
- Trial name
- NCT00350545
- Testing
- Rituximab, Prednisone, Cyclosporine A
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Stanford University
Rheumatoid Arthritis
An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis
To study the effects of T cell in peripheral blood of patients with RA undergoing selective B cell depletion have not been studied.
- Trial name
- NCT00555542
- Testing
- rituximab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chinese University of Hong Kong
Non-Hodgkins Lymphoma
Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
Researchers hope to learn if adding rituximab with high doses of chemotherapy and stem cell transplantation will help patients get rid of their lymphoma cells from the bone marrow and stem cell collections.
- Trial name
- NCT00856245
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Kansas Medical Center
Lymphoma
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00376961
- Testing
- rituximab, bortezomib, cyclophosphamide
- Where
- 147 sites in United States
- Volunteers
- 68 people
- Sponsor
- SWOG Cancer Research Network
Multiple Sclerosis
Safety of Switching From Rituximab to Ocrelizumab in MS Patients
This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least…
- Trial name
- NCT02980042
- Testing
- Ocrelizumab, Rituximab
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Rheumatoid Arthritis
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
The purpose of this study is to determine the PK/PD, efficacy and safety of GP2013 in patients with severe rheumatoid arthritis.
- Trial name
- NCT01274182
- Testing
- GP2013, MabThera, Rituxan
- Where
- 57 sites in United States, Argentina and 12 more
- Volunteers
- 312 people
- Sponsor
- Sandoz
Mantle Cell Lymphoma
Study of Mantle Cell Lymphoma Treatment by RiBVD
Study of First line mantle cell lymphoma treatment by Rituximab, Velcade, Bendamustine and Dexamethasone schema in patients older than 65 years or 18 to 65 years old who cannot or refuse receive conditioning regimen followed by…
- Trial name
- RIBVD (NCT01457144)
- Testing
- RiBVD
- Where
- France
- Volunteers
- 76 people
- Sponsor
- French Innovative Leukemia Organisation
Lymphoma, Mantle-Cell
Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma
The objective of the study is to demonstrate the safety, tolerability, and activity of Rituximab-Bendamustine-Cytarabine(R-BAC) regimen in patients with mantle cell lymphoma (MCL) aged 65 years or more, as well as in younger…
- Trial name
- NCT00992134
- Testing
- Rituximab, Bendamustine, Cytarabine
- Where
- Italy
- Volunteers
- 41 people
- Sponsor
- St. Bortolo Hospital
CLL, Chronic Lymphocytic Leukemia
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL
This is a trial in patients with previously untreated CLL. Eligible patients will receive Lenalidomide with a backbone of Fludarabine and Rituximab for 6 therapy cycles.
- Trial name
- NCT01703364
- Testing
- Lenalidomide
- Where
- 2 sites in Austria
- Volunteers
- 12 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Randomized double-blind controlled study of rituximab versus placebo in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) on chronic treatment with immunoglobulins.
- Trial name
- CIDPRIT (NCT06325943)
- Testing
- Rituximab
- Where
- Italy
- Volunteers
- 37 people
- Sponsor
- Istituto Clinico Humanitas
Ocular Cicatricial Pemphigoid
Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness.
- Trial name
- NCT00584935
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Alabama at Birmingham
CD20 Positive, Chronic Lymphocytic Leukemia
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
This phase I trial studies the best dose and how well bendamustine works with standard chemotherapy (fludarabine, rituximab) in treating participants with lymphoid cancers undergoing stem cell transplant.
- Conditions
- CD20 Positive, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT00880815
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bendamustine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Mantle Cell, Mantle Cell Lymphoma
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
This study will evaluate the effectiveness of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin-rituximab (EPOCH-R) chemotherapy plus bortezomib for treating mantle cell lymphoma, a cancer of white blood cells…
- Trial name
- NCT00114738
- Testing
- Rituximab (R), EPOCH, Bortezomib (B)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
This study will evaluate the safety and efficacy of MabThera in patients with active rheumatoid arthritis who have had an inadequate response or were intolerant to treatment with methotrexate.
- Trial name
- NCT00934648
- Testing
- rituximab [MabThera/Rituxan], methotrexate
- Where
- 5 sites in Morocco
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Large B-cell Diffuse Lymphoma of Testis
Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis
This trial is a phase II non-comparative study aimed to determine the feasibility and toxicity of the R-CHOP regimen in combination with intrathecal liposomal cytarabine and systemic intermediate-dose methotrexate followed by…
- Trial name
- IELSG30 (NCT00945724)
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate
- Where
- 22 sites in Italy, Switzerland
- Volunteers
- 54 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Hodgkin Lymphoma
Brentuximab for Newly Diagnosed Hodgkin Disease
The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).
- Trial name
- NCT02398240
- Testing
- Brentuximab Vedotin, Doxorubicin, Vincristine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mitchell Cairo
Ischemic Heart Disease, Myocardial Infarction
Rituximab in Patients With Acute ST-elevation Myocardial Infarction Study
RITA-MI aims to develop of a novel therapeutic concept to target the immune response in patients with acute myocardial infarction (MI) by depleting B-cells with a single injection of Rituximab which is approved for clinical use…
- Conditions
- Ischemic Heart Disease, Myocardial Infarction, Inflammation
- Trial name
- RITA-MI (NCT03072199)
- Testing
- RiTUXimab Injection
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Kidney Transplantation, Kidney Failure, Chronic
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
In small initial studies, combined kidney and bone marrow transplants from the same donor have permitted some individuals to stop taking anti-rejection medicines without rejecting their transplant.
- Trial name
- NCT00801632
- Testing
- Kidney Transplantation, Bone marrow transplantation, MEDI-507
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
This phase I/II trial is studying the side effects and best dose of oblimersen when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with relapsed or refractory…
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
- Trial name
- NCT00086944
- Testing
- oblimersen sodium, rituximab, ifosfamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)